News & Events
Featured Article
Sept 06, 2023 | News
Proteros biostructures and Orion Pharma agree on a long-term multi-target collaboration including the assembly of a joint novel and unique HTS small-molecule screening library with full chemistry support of Enamine
Proteros biostructures and Orion Pharma agree on a long-term multi-target collaboration including the assembly of a joint novel and unique HTS small-molecule screening library with full chemistry support of Enamine
NEWS & EVENTS
Sept 06, 2023
News
Proteros biostructures and Orion Pharma agree on a long-term multi-target collaboration including the assembly of a joint novel and unique HTS small-molecule screening library with full chemistry support of Enamine
Jan 09, 2023
News
Proteros receives minority investment from private equity firm Inflexion
Oct 25, 2022
News
Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases
May 16, 2022
News
Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca
December 13, 2021
News
Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under Covid-19 Discovery Research and License Agreement
Jun 02 2021
News
Proteros Enters into Oncology Collaboration and License Agreement with AstraZeneca
Apr 01 2021
News
Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
Oct 01 2020
News
Proteros Biostructures and X-Chem to Offer Comprehensive Joint Target-to-Lead Drug Discovery Services
Sept 01 2020
News
Proteros launches new cryo-EM facility to speed drug discovery
Sep 27 to Sep 30 2021
Event
Proteros speaks at the USA Discovery on Target Conference 2021
Nov 02 to Nov 04 2021
Event
We plan to attend the PEGS Europe Conference 2021
Coming soon
Event
We plan to attend the PSDI 2021 Conference
Stay in touch
Subscribe to our Newsletter to stay up-to-date with all of our latest news and events.